Neuraxpharm, controled by Permira, agrees on the divestment of Inke to Keensight Capital
27/04/2023 Press release NEURAXPHARM, CONTROLED BY PERMIRA, AGREES ON THE DIVESTMENT OF INKE TO KEENSIGHT CAPITAL Group (“Neuraxpharm”), the leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announced today that it has signed a binding agreement to divest Inke, a specialized inhalation active pharmaceutical ingredients (APIs) developer and…